

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 October 2024 (17.10.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/213091 A9



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)
A61K 47/69 (2017.01)

(21) International Application Number:

PCT/CN2024/087405

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/088101

13 April 2023 (13.04.2023) CN

(71) Applicant: GENEQUANTUM HEALTHCARE

(SUZHOU) CO., LTD. [CN/CN]; 5th Floor, Building D,
No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou,
Jiangsu 215123 (CN).

(72) Inventors: SUN, Yajun; 5th Floor, Building D, No. 398,

Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu
215123 (CN). SONG, Paul H.; 5th Floor, Building D, No.
398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiang-
su 215123 (CN). QIN, Gang; 5th Floor, Building D, No.

398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu
215123 (CN).

(74) Agent: NTD UNIVATION INTELLECTUAL PROP-

ERTY AGENCY LTD.; 10th Floor, Tower C, Beijing
Global Trade Center, 36 North Third Ring Road East,
Dongcheng District, Beijing 100013 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF

(57) Abstract: The present disclosure relates to a combination of
antibody-drug conjugate and anti-PD-1 antibody, and use there-
of.




Figure 11

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

19 December 2024 (19.12.2024)

(15) Information about Correction:

see Notice of 19 December 2024 (19.12.2024)